Kandidiasis Oral & Esofagus

01Pathophysiology

Candida albicans is a dimorphic fungal organism that exists as a normal commensal of the human oropharynx, gastrointestinal tract, and genitourinary system. Under normal circumstances, an intact immune system and the competing bacterial flora keep Candida colonization in check. Disease occurs when this balance is disrupted.

The transition from colonization to infection hinges on two factors: host immune compromise and Candida's morphological switch from yeast form to the invasive hyphal (pseudohyphal) form. This switch is the reason KOH preparations reveal pseudohyphae rather than simple budding yeast alone. The hyphal form produces adhesins and hydrolytic enzymes (secreted aspartyl proteinases and phospholipases) that allow the organism to adhere to and penetrate mucosal epithelium.

Cell-mediated immunity, primarily through CD4+ T-helper cells and their Th1/Th17 cytokine responses, is the principal defense against mucocutaneous candidiasis. This is why HIV/AIDS patients with declining CD4 counts develop thrush, and why esophageal candidiasis is classified as an AIDS-defining illness (typically appearing when CD4 drops below 100 to 200 cells/mm³). The loss of T-cell surveillance allows unchecked fungal proliferation across mucosal surfaces.

In patients using inhaled corticosteroids, the mechanism is local immunosuppression and alteration of the oropharyngeal microenvironment. Steroids suppress local mucosal immune responses and promote glucose availability in saliva, both of which favor Candida overgrowth. This is why patients are instructed to rinse the mouth after using an inhaler, a frequently tested preventive measure.

Broad-spectrum antibiotics contribute by eliminating competing bacterial flora that normally suppress Candida colonization, allowing the organism to proliferate unopposed. This mechanism is analogous to Clostridioides difficile overgrowth following antibiotic use.

The white plaques seen clinically are composed of desquamated epithelial cells, fungal organisms (yeast and pseudohyphae), fibrin, and inflammatory debris. The ability to scrape these plaques off distinguishes thrush from other white oral lesions such as oral hairy leukoplakia, which cannot be scraped off.

When infection extends into the esophagus, the same invasive process causes mucosal inflammation and ulceration, producing the cardinal symptoms of odynophagia and dysphagia. Esophageal disease can exist without visible oral involvement, a point that frequently appears in exam vignettes.

02Classification and Clinical Manifestation

It is important to recognize that pseudomembranous candidiasis is the most commonly tested form. The distinguishing feature of plaques that scrape off is a classic discriminator on the exam. Erythematous candidiasis is a common distractor because it lacks the white plaques, making it easier to confuse with other causes of oral erythema.

03Diagnostic Workup

Oral candidiasis is primarily a clinical diagnosis. When a patient presents with the classic white, removable plaques on an erythematous base in an appropriate clinical setting (immunosuppression, inhaled steroid use, antibiotic exposure), the diagnosis can be made at the bedside. A KOH preparation of the scraped material confirms the diagnosis by demonstrating pseudohyphae and budding yeast. Fungal culture is generally not required for straightforward presentations.

Esophageal candidiasis follows a different diagnostic pathway, and this distinction is heavily tested. In an HIV-positive patient presenting with odynophagia and/or dysphagia, the best initial step is an empiric trial of oral fluconazole, not endoscopy. This approach is both cost-effective and diagnostic: if symptoms resolve within 5 to 7 days, the diagnosis of esophageal candidiasis is confirmed and no further workup is needed.

Upper endoscopy is reserved for patients who fail to respond to the empiric fluconazole trial. On endoscopy, the classic finding is small, raised, white-yellow plaques on an erythematous and sometimes friable esophageal mucosa. Biopsy and brushings demonstrate yeast forms and pseudohyphae invading the squamous epithelium, which is the gold standard for definitive diagnosis. Endoscopy also helps rule out other causes of esophageal symptoms in immunocompromised patients, such as CMV esophagitis (large, deep, linear ulcers) or HSV esophagitis (small, shallow, well-circumscribed "volcano-like" ulcers).

A barium swallow may show a "shaggy" or irregular esophageal contour but is neither sensitive nor commonly tested as a first-line study.

04Management and Treatment

Acute management of mild oropharyngeal candidiasis begins with topical therapy. Clotrimazole troches and nystatin suspension are both acceptable first-line agents. These work by direct contact with the mucosal surface and carry minimal systemic side effects. Patients should be advised not to eat or drink for 20 to 30 minutes after application.

For moderate-to-severe oral disease or any patient with significant immunosuppression, oral fluconazole is the preferred agent. Fluconazole is well-absorbed orally, has excellent bioavailability, and achieves reliable mucosal concentrations. The standard regimen is a 200 mg loading dose followed by 100 to 200 mg daily for 7 to 14 days.

Esophageal candidiasis always requires systemic therapy; topical agents do not reach the esophageal mucosa adequately. Oral fluconazole remains the first-line treatment. For patients who cannot tolerate oral intake, intravenous fluconazole is used. If the patient fails fluconazole therapy (defined as no clinical improvement after 7 days of adequate dosing), the regimen should be switched to an echinocandin (micafungin, caspofungin, or anidulafungin). Echinocandins inhibit beta-1,3-glucan synthesis in the fungal cell wall and are effective against most Candida species, including many azole-resistant strains.

Amphotericin B is reserved as a last-resort agent due to its nephrotoxicity and infusion-related adverse effects. It is used only when both azoles and echinocandins have failed.

Contraindications and cautions:

• Fluconazole in pregnancy: Fluconazole is teratogenic (FDA category D for prolonged, high-dose use) and should be avoided in the first trimester. Topical agents like nystatin are preferred for pregnant patients with oral candidiasis.

• Azole drug interactions: Fluconazole is a potent inhibitor of CYP2C9, CYP2C19, and CYP3A4. It interacts with warfarin (increased INR), statins, calcineurin inhibitors (tacrolimus, cyclosporine), and certain anticonvulsants.

• Echinocandins and hepatotoxicity: Liver function should be monitored during prolonged use.

Long-term management focuses on addressing the underlying cause of immunosuppression. In HIV/AIDS patients, initiating or optimizing antiretroviral therapy to restore CD4 counts above 200 cells/mm³ is the single most important step to prevent recurrence. Chronic fluconazole suppression (100 to 200 mg three times per week) can be considered in patients with frequent recurrences but is generally discouraged because of the risk of selecting for azole-resistant Candida species.

For patients on inhaled corticosteroids, counseling on proper inhaler technique and consistent mouth rinsing after each use is the key preventive intervention.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The most common way students lose points on oral and esophageal candidiasis questions is by ordering endoscopy too early. When an HIV-positive patient presents with odynophagia and a low CD4 count, the best initial step is always an empiric trial of fluconazole, not endoscopy. Endoscopy is indicated only after failure of empiric therapy. This "treat first, scope second" approach is a core testing principle for esophageal candidiasis in immunocompromised patients.

A second frequent trap involves distinguishing oral candidiasis from oral hairy leukoplakia. Both present as white oral lesions in HIV patients. The discriminator is mechanical: candidal plaques scrape off; oral hairy leukoplakia does not. If a vignette mentions a white lesion on the lateral tongue that is non-removable, the answer is oral hairy leukoplakia (EBV-related), not thrush.

Students should also recognize that esophageal candidiasis is an AIDS-defining illness, regardless of whether oral thrush is present. A vignette can present esophageal candidiasis without any visible oral findings, and this should not cause hesitation.

Another tested concept is the prevention of oral candidiasis in patients using inhaled corticosteroids. When a patient on an inhaled steroid develops thrush, the question is often asking for the preventive measure (mouth rinsing after inhaler use) rather than the treatment. Recognizing this framing is important.

Finally, for refractory disease, the escalation ladder is testable: topical agents to fluconazole to echinocandins to amphotericin B. Students who jump directly to amphotericin B without first trying an echinocandin will select the wrong answer. The core competency being assessed is the ability to sequence antifungal therapy correctly and to recognize when empiric treatment is appropriate before invasive diagnostics.